These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 30323891)

  • 21. The Oxygen-Generating Calcium Peroxide-Modified Magnetic Nanoparticles Attenuate Hypoxia-Induced Chemoresistance in Triple-Negative Breast Cancer.
    Cheng FY; Chan CH; Wang BJ; Yeh YL; Wang YJ; Chiu HW
    Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33546453
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cannabidiol stimulates Aml-1a-dependent glial differentiation and inhibits glioma stem-like cells proliferation by inducing autophagy in a TRPV2-dependent manner.
    Nabissi M; Morelli MB; Amantini C; Liberati S; Santoni M; Ricci-Vitiani L; Pallini R; Santoni G
    Int J Cancer; 2015 Oct; 137(8):1855-69. PubMed ID: 25903924
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synergistic Effect of SH003 and Doxorubicin in Triple-negative Breast Cancer.
    Woo SM; Kim AJ; Choi YK; Shin YC; Cho SG; Ko SG
    Phytother Res; 2016 Nov; 30(11):1817-1823. PubMed ID: 27476488
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Increasing intratumor C/EBP-β LIP and nitric oxide levels overcome resistance to doxorubicin in triple negative breast cancer.
    Salaroglio IC; Gazzano E; Abdullrahman A; Mungo E; Castella B; Abd-Elrahman GEFA; Massaia M; Donadelli M; Rubinstein M; Riganti C; Kopecka J
    J Exp Clin Cancer Res; 2018 Nov; 37(1):286. PubMed ID: 30482226
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Minocycline, a putative neuroprotectant, co-administered with doxorubicin-cyclophosphamide chemotherapy in a xenograft model of triple-negative breast cancer.
    Himmel LE; Lustberg MB; DeVries AC; Poi M; Chen CS; Kulp SK
    Exp Toxicol Pathol; 2016 Oct; 68(9):505-515. PubMed ID: 27555377
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunohistochemical co-expression status of cytokeratin 5/6, androgen receptor, and p53 as prognostic factors of adjuvant chemotherapy for triple negative breast cancer.
    Maeda T; Nakanishi Y; Hirotani Y; Fuchinoue F; Enomoto K; Sakurai K; Amano S; Nemoto N
    Med Mol Morphol; 2016 Mar; 49(1):11-21. PubMed ID: 26009308
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combination of the novel histone deacetylase inhibitor YCW1 and radiation induces autophagic cell death through the downregulation of BNIP3 in triple-negative breast cancer cells in vitro and in an orthotopic mouse model.
    Chiu HW; Yeh YL; Wang YC; Huang WJ; Ho SY; Lin P; Wang YJ
    Mol Cancer; 2016 Jun; 15(1):46. PubMed ID: 27286975
    [TBL] [Abstract][Full Text] [Related]  

  • 28. microRNA-761 induces aggressive phenotypes in triple-negative breast cancer cells by repressing TRIM29 expression.
    Guo GC; Wang JX; Han ML; Zhang LP; Li L
    Cell Oncol (Dordr); 2017 Apr; 40(2):157-166. PubMed ID: 28054302
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Substance P Receptor Signaling Mediates Doxorubicin-Induced Cardiomyocyte Apoptosis and Triple-Negative Breast Cancer Chemoresistance.
    Robinson P; Kasembeli M; Bharadwaj U; Engineer N; Eckols KT; Tweardy DJ
    Biomed Res Int; 2016; 2016():1959270. PubMed ID: 26981525
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Apatinib-induced NF-κB inactivation sensitizes triple-negative breast cancer cells to doxorubicin.
    Tang D; Ma J; Chu Z; Wang X; Zhao W; Zhang Q
    Am J Transl Res; 2020; 12(7):3741-3753. PubMed ID: 32774731
    [TBL] [Abstract][Full Text] [Related]  

  • 31. HAGE in Triple-Negative Breast Cancer Is a Novel Prognostic, Predictive, and Actionable Biomarker: A Transcriptomic and Protein Expression Analysis.
    Abdel-Fatah TM; McArdle SE; Agarwal D; Moseley PM; Green AR; Ball GR; Pockley AG; Ellis IO; Rees RC; Chan SY
    Clin Cancer Res; 2016 Feb; 22(4):905-14. PubMed ID: 26240276
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PKD1 is a potential biomarker and therapeutic target in triple-negative breast cancer.
    Spasojevic C; Marangoni E; Vacher S; Assayag F; Meseure D; Château-Joubert S; Humbert M; Karam M; Ricort JM; Auclair C; Regairaz M; Bièche I
    Oncotarget; 2018 May; 9(33):23208-23219. PubMed ID: 29796183
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Androgen Receptor Promotes Cellular Proliferation by Suppression of G-Protein Coupled Estrogen Receptor Signaling in Triple-Negative Breast Cancer.
    Shen Y; Yang F; Zhang W; Song W; Liu Y; Guan X
    Cell Physiol Biochem; 2017; 43(5):2047-2061. PubMed ID: 29059676
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The TRPV2 cation channels: from urothelial cancer invasiveness to glioblastoma multiforme interactome signature.
    Santoni G; Amantini C; Maggi F; Marinelli O; Santoni M; Nabissi M; Morelli MB
    Lab Invest; 2020 Feb; 100(2):186-198. PubMed ID: 31653969
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CLDN1 Sensitizes Triple-Negative Breast Cancer Cells to Chemotherapy.
    Lemesle M; Geoffroy M; Alpy F; Tomasetto CL; Kuntz S; Grillier-Vuissoz I
    Cancers (Basel); 2022 Oct; 14(20):. PubMed ID: 36291810
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Current strategy for triple-negative breast cancer: appropriate combination of surgery, radiation, and chemotherapy.
    Yagata H; Kajiura Y; Yamauchi H
    Breast Cancer; 2011 Jul; 18(3):165-73. PubMed ID: 21290263
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Metformin sensitizes triple-negative breast cancer to proapoptotic TRAIL receptor agonists by suppressing XIAP expression.
    Strekalova E; Malin D; Rajanala H; Cryns VL
    Breast Cancer Res Treat; 2017 Jun; 163(3):435-447. PubMed ID: 28324269
    [TBL] [Abstract][Full Text] [Related]  

  • 38. TRPV2: A Cancer Biomarker and Potential Therapeutic Target.
    Siveen KS; Nizamuddin PB; Uddin S; Al-Thani M; Frenneaux MP; Janahi IA; Steinhoff M; Azizi F
    Dis Markers; 2020; 2020():8892312. PubMed ID: 33376561
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PITX2 DNA-methylation predicts response to anthracycline-based adjuvant chemotherapy in triple-negative breast cancer patients.
    Absmaier M; Napieralski R; Schuster T; Aubele M; Walch A; Magdolen V; Dorn J; Gross E; Harbeck N; Noske A; Kiechle M; Schmitt M
    Int J Oncol; 2018 Mar; 52(3):755-767. PubMed ID: 29328369
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Induction of cell cycle arrest and inflammatory genes by combined treatment with epigenetic, differentiating, and chemotherapeutic agents in triple-negative breast cancer.
    Merino VF; Cho S; Nguyen N; Sadik H; Narayan A; Talbot C; Cope L; Zhou XC; Zhang Z; Győrffy B; Sukumar S
    Breast Cancer Res; 2018 Nov; 20(1):145. PubMed ID: 30486871
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.